©2022 Stanford Medicine
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
Trial ID: NCT04072315
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
A Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF
- Diagnosis of IPF, within 5 years prior to Screening,
- FVC %predicted ≥45%; historical FVC for entry in the study is permitted if within 1
month of screening.
- DLco (hemoglobin-adjusted) ≥30%; historical DLco for entry in the study is permitted
if within 1 month of screening.
- Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,if
on a stable dose for at least 3 months
- Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents
not approved for that indication by the FDA
- Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC
- Clinical evidence of active infection, including but not limited to bronchitis,
pneumonia, sinusitis that can affect FVC measurement or IPF progression
- Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months
- Smoking of any kind within 3 months of Screening
radiation: Knottin tracer
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Joshua Mooney, MD